John Evans is Chief Executive Officer of Beam Therapeutics (NASDAQ: BEAM).  Mr. Evans was previously an early employee and member of the leadership team at Agios Pharmaceuticals, where he helped develop IDHIFA and TIBSOVO, two IDH inhibitors for the treatment of AML. He also helped initiate and lead Agios’ landmark alliance with Celgene, and co-led Agios’ expansion into rare genetic diseases. Mr. Evans holds an M.B.A. in Healthcare Management from Wharton, a Masters in Biotechnology from the University of Pennsylvania, and a B.A. in English with distinction from Yale University.